Adagene Inc. (ADAG) Opens Phase 1 Trial of ADG126 Combination in Colorectal Cancer
Adagene Inc. (ADAG) and City of Hope began a Phase 1 trial of ivonescimab and ADG126 for advanced colorectal cancer. The study will include up to 36 patients.
How this was made

The 30-second read
Why it matters
This is a pipeline milestone that can support longer-term valuation optionality, but it is not yet evidence of clinical benefit.
Market read
Traders may view the trial start as incremental pipeline progress, but without interim data it is unlikely to drive a major repricing immediately.
What to watch
Key missing items are dosing schedule, safety endpoints, and whether ivonescimab plus ADG126 has prior signals in this exact setting.
Background
The piece describes the launch of an investigator-initiated Phase 1 trial for ivonescimab plus ADG126 in advanced microsatellite stable colorectal cancer.
Ticker impact
Adagene launched an investigator-initiated Phase 1 trial combining ivonescimab and ADG126 in advanced microsatellite stable colorectal cancer, enrolling up to 36 patients.
Likely limited near-term reaction as investors wait for dose selection, safety, and any antitumor signals.
The article discloses a Phase 1 start and enrollment size only. Without interim results, the news mainly updates pipeline progress rather than fundamentals.
Market effects
Adds incremental momentum to the oncology immunotherapy and colorectal cancer trial landscape, but with no cross-company read-through provided.
No specific regional market linkage mentioned.
Limited global impact; this is a single-company early clinical development update.
Counterpoint
Phase 1 investigator-initiated studies can be slower and less predictive than company-sponsored pivotal programs, so the market may discount the catalyst.
Key entities
- companyAdagene Inc.
Sponsor of the Phase 1 trial for ivonescimab and ADG126 in advanced microsatellite stable colorectal cancer.
- research_institutionCity of Hope
Co-launched the investigator-initiated Phase 1 trial with Adagene.
- drug_candidateADG126
Adagene’s investigational candidate used in combination in the Phase 1 study.
- drug_candidateivonescimab
Combination partner in the Phase 1 trial.
